Market Newsdesk

• One of the industry’s first “one-box” EyeQ5 front-facing camera systems
• Magna’s electronics and camera expertise, Mobileye’s image-processing technology
• Magna ADAS systems are found on more than 250 vehicle models on the road today

TROY, Mich., Nov. 24, 2020 (GLOBE NEWSWIRE) — A premium automaker in Europe will soon be able to offer industry-leading driver assistance features across a larger portion of its vehicle lineup, thanks to the next generation of camera-based driver assistance from Magna.

The Magna Gen5 “one-box” solution is a Mobileye EyeQ5-based system – one of the industry’s first where the forward-facing camera and related software are contained in a single assembly. Benefits include lower cost, simplified installation on the assembly line, and the ability for the technology to be applied to a wider range of an automaker’s lineup. The system will provide drivers with safety and convenience features such as adaptive cruise control, automatic emergency braking and pedestrian detection. 

As with previous generations, the system combines Magna’s electronics and camera expertise with Mobileye’s system-on-chip (SoC) image-processing technology. The camera features a 120-degree, 8-megapixel optical path, while Magna has continued to refine its world-class camera manufacturing processes to achieve the quality and volumes required of global vehicle platforms. Mobileye collaborated with Magna engineers to ensure that the EyeQ5 met and exceeded new requirements related to the launch program.

“At Magna, our ADAS capability has been built on automotive cameras, evidenced by more than 500 U.S. patents in the last 15 years,” said Uwe Geissinger, President of Magna Electronics. “As demonstrated by our long collaboration with Mobileye and the introduction of our new Gen5 system, we’re constantly working to deliver innovative systems to our customers and help make vehicles safer and more enjoyable to drive.”

“We have been working with Magna on camera-based ADAS since 2007, and our collaboration continues to provide leading-edge driver-assistance features,” said Erez Dagan, Executive Vice President for Products and Strategy at Mobileye. “This latest system represents a new level of performance and functionality, and we’re already looking for ways to make subsequent generations even better.”

Magna provides global automakers with ADAS technologies – including the PACE Award-winning Trailer Angle Detection, Automatic Emergency Braking, and rearview object and pedestrian detection – to more than 250 vehicle models on the road today.

TAGS
Automotive camera systems, camera-based ADAS, automotive electronics

INVESTOR CONTACT
Louis Tonelli, Vice President, Investor Relations
[email protected], (+1) 905.726.7035

MEDIA CONTACT
Tracy Fuerst, Vice President, Corporate Communications & PR
[email protected], (+1) 248.631.7004

ABOUT MAGNA
We are a mobility technology company. We have over 157,000 entrepreneurial-minded employees, 344 manufacturing operations and 93 product development, engineering and sales centres in 27 countries. We have complete vehicle engineering and contract manufacturing expertise, as well as product capabilities that include body, chassis, exteriors, seating, powertrain, active driver assistance, electronics, mechatronics, mirrors, lighting and roof systems. Our common shares trade on the Toronto Stock Exchange (MG) and the New York Stock Exchange (MGA). For further information about Magna, visit www.magna.com.

THIS RELEASE MAY CONTAIN STATEMENTS WHICH CONSTITUTE “FORWARD-LOOKING STATEMENTS” UNDER APPLICABLE SECURITIES LEGISLATION AND ARE SUBJECT TO, AND EXPRESSLY QUALIFIED BY, THE CAUTIONARY DISCLAIMERS THAT ARE SET OUT IN MAGNA’S REGULATORY FILINGS. PLEASE REFER TO MAGNA’S MOST CURRENT MANAGEMENT’S DISCUSSION AND ANALYSIS OF RESULTS OF OPERATIONS AND FINANCIAL POSITION, ANNUAL INFORMATION FORM AND ANNUAL REPORT ON FORM 40-F, AS REPLACED OR UPDATED BY ANY OF MAGNA’S SUBSEQUENT REGULATORY FILINGS, WHICH SET OUT THE CAUTIONARY DISCLAIMERS, INCLUDING THE RISK FACTORS THAT COULD CAUSE ACTUAL EVENTS TO DIFFER MATERIALLY FROM THOSE INDICATED BY SUCH FORWARD-LOOKING STATEMENTS. THESE DOCUMENTS ARE AVAILABLE FOR REVIEW ON MAGNA’S WEBSITE AT 

WWW.MAGNA.COM

.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/cf925241-95aa-4512-be68-d2071c01bcb3

WAYNE, N.J., Nov. 24, 2020 (GLOBE NEWSWIRE) — Konica Minolta Healthcare Americas, Inc. announces that Centro Rossi, a leading healthcare provider in Argentina with 13 locations throughout Greater Buenos Aires, is implementing the Exa® Enterprise Imaging Platform throughout all of its centers. Konica Minolta also announced an agreement with Habitat Evolution to distribute the Exa Enterprise Imaging Platform within all regions of Argentina.

Founded by Dr. Enrique Martín Rossi in 1980, Centro Rossi has led the modernization of diagnostic imaging services and elevated the quality of care in Argentina by acquiring state-of-the-art systems and retaining highly trained staff. The organization selected the Exa Platform because it is customizable and adaptable to the specific needs of the region. Konica Minolta and Centro Rossi will collaborate to continue enhancing and evolving the Exa Platform for the Latin American market.

“At Centro Rossi, we consistently seek the best solutions to provide our patients with the highest standard of care,” says Santiago Enrique Rossi, MD, Medical Director at Centro Rossi. “The Exa Enterprise Imaging Platform will help us provide better care for our patients and referring physicians and we are very proud to work with Konica Minolta to further innovate and bring new imaging informatics solutions to the Latin American healthcare market.

The Exa Platform is designed to allow for the rapid adoption of new technologies and capabilities as customer and market needs evolve. With a web-based, Zero-Footprint platform, the Exa Platform uses Server-Side Rendering to facilitate the fast transfer of large imaging studies regardless of the internet connection. The diagnostic-quality Zero Footprint viewer provides access to patient data from any device and from any location with an internet connection. As a leader in the region, Centro Rossi is uniquely positioned to provide insights on the strategic direction of Healthcare IT in Latin America.

“As we introduce Konica Minolta’s Healthcare IT solutions to the region, this partnership provides new opportunities to innovate our Exa Enterprise Imaging Platform and introduce new technologies to meet the unique and evolving needs of the local market. Centro Rossi’s patient-centric business model aligns with ours and we are very excited to enter into this strategic partnership with one of the most prestigious imaging center organizations in Latin America,” says Antonio Uzcátegui, Director of Health Technology for Latin America at Konica Minolta Healthcare Americas, Inc.

Regarding the partnership with Habitat Evolution, Daniela Prosperi, Director of Operations for Habitat Evolution, says signing a distribution agreement with a multinational company like Konica Minolta Healthcare underscores the importance of developing markets even in the midst of a difficult business climate. “It’s all about innovation, and this is only the first step of many to come with this collaboration,” adds Prosperi. “The Habitat Evolution team is proud and committed to make this partnership a complete success.”

Ernesto Márquez, General Manager of the Latin American Region for Konica Minolta Healthcare, expressed his enthusiasm for the new distributor partnership. “Habitat Evolution’s experienced professionals are uniquely qualified to collaborate with our organization to further develop our Healthcare IT business footprint in Argentina.”

About Konica Minolta Healthcare Americas, Inc.

Konica Minolta Healthcare is a world-class provider and market leader in medical diagnostic imaging and healthcare information technology. With over 75 years of endless innovation, Konica Minolta is globally recognized as a leader providing cutting-edge technologies and comprehensive support aimed at providing real solutions to meet customer’s needs and helping make better decisions sooner. Konica Minolta Healthcare Americas, Inc., headquartered in Wayne, NJ, is a unit of Konica Minolta, Inc. (TSE:4902). For more information on Konica Minolta Healthcare Americas, Inc., please visit www.konicaminolta.com/medicalusa.

Contact: 
Mary Beth Massat                                                        
Massat Media
224.578.2388
www.konicaminolta.com/medicalusa

VANCOUVER, British Columbia, Nov. 24, 2020 (GLOBE NEWSWIRE) — Cypress Development Corp. (TSX-V:CYP) (OTCQB:CYDVF) (Frankfurt:C1Z1) (“Cypress” or “the Company”) reports the completion of additional metallurgical testing following the positive Prefeasibility Study (PFS) published on the Company’s 100%-owned Clayton Valley Lithium Project in Nevada, USA. The testing was conducted at Continental Metallurgical Services in Montana and NORAM Engineering in British Columbia, in preparation for the Company’s pilot plant program as outlined in the PFS.

Highlights

• Testing resulted in 80.2% extraction of lithium when a sodium chloride solution was used instead of distilled water in leaching claystone under Cypress’ sulfuric acid leach process.
• Lithium in the resulting leach solution was successfully concentrated at levels comparable to the PFS with limited interference by chlorides and other minerals present.
• The ability to tolerate high chloride levels in the process is significant because it allows the consideration of a wider range of resources for water supply including geothermal solutions and lithium-bearing brine.
• An alternate approach was tested using hydrochloric acid instead of sulfuric acid in leaching the claystone. A lithium extraction of 85.3% was obtained, suggesting hydrochloric acid may be a more effective reagent if high chloride levels are present in the water used in leaching.

“The test results are significant and demonstrate the Cypress process will work with high saline water sources,” said Cypress CEO Bill Willoughby.

“The observation that leaching clay is more efficient when using hydrochloric acid with a saline brine is intriguing as it suggests a way to eliminate sulfuric acid from the process. This would benefit the project by eliminating the purchasing and transportation of sulfur which are limiting constraints on increasing the scale of production. Further work, however, is needed.” The Company is conducting additional tests and analyses to determine if there is an alternate process that could be tested in parallel with the pilot plant program.

“We continue working toward the next stage of development with the pilot plant program,” said Bill Willoughby. “Our objective remains to initiate the program and work to advance the project to a full feasibility study. We have now shown we have a lithium deposit and an extraction process which are compatible with high saline water sources.”

Qualified Person:

Todd Fayram, MMSA-QP, is the qualified person as defined by National Instrument 43-101 and has approved the technical information in this release.

About Cypress Development Corp.:

Cypress Development Corp. is a publicly traded exploration company focused on developing the Company’s 100%-owned Clayton Valley Lithium Project in Nevada. Exploration and development by Cypress discovered a world-class resource of lithium-bearing claystone adjacent to the Albemarle Silver Peak mine, North America’s only lithium brine operation. The size of the resource makes the Clayton Valley Project a premier source that has the potential to impact the supply of lithium for the fast-growing global energy storage battery market.

Clayton Valley Lithium Project, Nevada claims map:

https://www.cypressdevelopmentcorp.com/site/assets/files/3573/cyp_cm_series_drill_hole_map_2020.jpg

Cypress Development Corp. has approximately 98.4 million shares issued and outstanding.

To find out more about Cypress Development Corp. (TSX-V: CYP), visit our website at www.cypressdevelopmentcorp.com.

CYPRESS DEVELOPMENT CORP.

“
Dr. Bill Willoughby
”

                                        
WILLIAM WILLOUGHBY, PhD., PE
Chief Executive Officer

For further information contact myself or:
Don Myers
Cypress Development Corp.
Director, Corporate Communications
Telephone: 604-639-3851
Toll Free: 800-567-8181
Facsimile: 604-687-3119
Email: [email protected]

NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THE CONTENT OF THIS NEWS RELEASE.

This release includes certain statements that may be deemed to be “forward-looking statements”. All statements in this release, other than statements of historical facts, that address events or developments that management of the Company expects, are forward-looking statements. Although management believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance, and actual results or developments may differ materially from those in the forward-looking statements. The Company undertakes no obligation to update these forward-looking statements if management’s beliefs, estimates or opinions, or other factors, should change. Factors that could cause actual results to differ materially from those in forward-looking statements, include market prices, exploration and development successes, continued availability of capital and financing, and general economic, market or business conditions. Please see the public filings of the Company at www.sedar.com for further information.

• MDSAP is the highest quality and regulatory
  standard
  in the medical device industry 

TORONTO, Nov. 24, 2020 (GLOBE NEWSWIRE) — Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late stage theranostic company advancing therapeutic options for sepsis and septic shock, as well as commercializing a new proprietary platform targeting the renal replacement therapy market, today announced that its wholly owned subsidiary, Dialco Medical Inc. (“Dialco”) received its Medical Device Single Audit Program (“MDSAP”) certification for “the design, manufacture, installation and service of equipment for extracorporeal blood purification and its related disposable” under ISO 13485 for Canada (Medical Devices Regulations – Part 1- SOR 98/282) and United States (21 CFR 820, 21 CFR 803, 21 CFR 806, 21 CFR 807 (Subparts A to D), 21 CFR 821).

MDSAP allows the conduct of a single regulatory audit of a medical device manufacturers quality management system to satisfy the requirements of multiple regulatory jurisdictions or authorities to enable appropriate regulatory oversight of medical device manufacturers’ quality management systems while minimizing regulatory burden on the industry. The program was developed by the International Medical Device Regulators Forum and currently representatives from The Therapeutic Goods Administration in Australia; Brazil’s Agência Nacional de Vigilância Sanitária; Health Canada Canadian Medical Device Regulations; Japan’s Ministry of Health, Labour and Welfare and Pharmaceutical and Medical Devices Agency, and the U.S. Food and Drug Administration, Center for Devices and Radiological Health participate in the program.

“On Dialco’s continued commercialization path, MDSAP and ISO 13485 certifications represent important milestones. Not only does certification through these programs validate our ongoing commitment to maintaining the highest quality assurance standards within the medical device industry, but MDSAP certification is also a Health Canada mandated requirement to sell medical devices in Canada,” said Dr. Gualtiero Guadagni, President of Dialco. “Additionally, Dialco’s receipt of its own MDSAP certification supports Dialco’s continuous pathway of achieving a fully independent operating structure.”

About Spectral
and
Dialco

Spectral is a Phase III company seeking U.S. FDA approval for its unique product for the treatment of patients with septic shock, Toraymyxin™ (“PMX”). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s Endotoxin Activity Assay (EAA™), the only FDA cleared diagnostic for the risk of developing sepsis.

PMX is approved for therapeutic use in Japan and Europe, and has been used safely and effectively on more than 200,000 patients to date. In March 2009, Spectral obtained the exclusive development and commercial rights in the U.S. for PMX, and in November 2010, signed an exclusive distribution agreement for this product in Canada. Approximately 330,000 patients are diagnosed with severe sepsis and septic shock in North America each year.

Spectral, through its wholly owned subsidiary, Dialco Medical Inc. (“Dialco”), is also commercializing a new proprietary platform, “SAMI”, targeting the renal replacement therapy (“RRT”) market. Dialco is also seeking regulatory approval for in-home use of “DIMI” which is based on the same RRT platform, but will be intended for home hemodialysis use. “DIMI” recently received its FDA 510k clearance for use in hospital and clinical settings.

Spectral is listed on the Toronto Stock Exchange under the symbol EDT. For more information, please visit www.spectraldx.com.

Forward-looking statement

Information
in
this
news
release
that
is
not
current
or
historical
factual
information
may
constitute
forward-looking information
or forward looking statements
within the meaning of securities laws. Implicit in this information, particularly in respect of the
future outlook
of Spectral and anticipated events or results, are assumptions based on beliefs of
Spectral’s
senior management
as
well
as
information
currently
available
to
it.
While
these
assumptions
were
considered
reasonable by Spectral at the time of preparation, they may prove to be incorrect.
Readers are cautioned that actual results are
subject
to
a
number
of
risks
and
uncertainties,
including
the
availability
of
funds
and
resources
to
pursue
R&D projects, the successful and timely completion of clinical studies, the ability of Spectral to take advantage of business opportunities in the biomedical industry, the granting of necessary approvals by regulatory authorities
including but not limited to the ongoing impact of COVID-19.
Actual results could differ materially from what is currently expected, and readers
are cautioned
not to place undue reliance on these forward-looking statements. Except as required by law, the Company disclaims any obligation to update or revise any forward-looking statements. Reference is also made to the other risks and uncertainties that may affect the
Company which
are more fully described in
Spectral’s
Annual Information Form dated March 26, 2020 and other filings of Spectral with the securities regulatory authorities which are available at www.sedar.com.

The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this statement.

For further information, please contact:

Dr. Paul Walker President and CEO Spectral Medical Inc. 416-626-3233 ext. 2100 [email protected]

Mr. Chris Seto COO & CFO Spectral Medical Inc. 416-626-3233 ext. 2004 [email protected]

Ali Mahdavi Capital Markets & Investor Relations 416-962-3300 [email protected]

LARGO, FL, Nov. 24, 2020 (GLOBE NEWSWIRE) — via NewMediaWire — Today, Leone Asset Management (OTC PINK: LEON) Subsidiary Go Epic Health, Inc., announced that they have entered into an International Distribution Agreement with Canavation Product Group, Inc.

The distribution agreement will begin with Go Epic Health’s Flagship product Cholesterade®.  Canavation Product Group will be handling all aspects of manufacturing, marketing and distribution of Cholesterade® throughout the United Kingdom and the European Union. 

James Price, Chairman and CEO of Leone Asset, stated, “We have been very patient with finding the correct partner to handle distribution of Cholesterade® in International Markets. We are extremely pleased to have entered into this agreement with Canavation.  The company as well as management have a deep history and knowledge of distributing consumer products throughout the EU and the UK and we anticipate a very long and mutually profitable relationship.”

About Leone Asset Management 

Leone Asset Management, Inc., is a multi-national, multi-industry conglomerate with subsidiary companies that operate in Health and Wellness, Media & Communications, Infrastructure development, agriculture management and mining exploration. For additional information, please visit www.leoneasset.com. 

About Canavation Product Group

Canavation is an award-winning group of wellness companies and joint ventures that include an international product development arm, cGMP nutraceutical manufacturing facilities and a multinational sales and distribution pipeline.  We develop a broad range of highly differentiated consumer products leveraging rare ingredients and delivery systems.  This includes a patent-protected cannabinoid technology offering 18x higher bioavailability and catalog of future rare cannabinoids.  For additional information, please visit www.canavation.com

Forward-Looking Statements Disclosure:

This press release may contain “forward-looking statements” within the meaning of the federal securities laws. In this context, forward-looking statements may address the Company’s expected future business and financial performance, and often contain words such as “anticipates,” “beliefs,” “estimates,” “expects,” “intends,” ” plans,” “seeks,” “will,” and other terms with similar meaning. These forward-looking statements by their nature address matter that are, to different degrees, uncertain. Although the Company believes that the assumptions upon which its forward-looking statements based are reasonable, it can provide no assurances that these assumptions will prove to be correct. All forward-looking statements in this press release are expressly qualified by such cautionary statements, risk, and uncertainties, and by reference to the underlying assumptions.

Contact:

James Price

[email protected]

727-581-1500

NEWPORT BEACH, Calif., Nov. 24, 2020 (GLOBE NEWSWIRE) — Collectors Universe, Inc. (“Collectors”” or the “Company”) (NASDAQ: CLCT), a leading provider of value-added authentication and grading services to dealers and collectors of collectibles, is reminding its stockholders that the Company’s 2020 Annual Stockholders Meeting, to be held on Thursday, December 10, 2020, at 10:00 a.m. (Pacific Time), will be a virtual meeting that will be conducted exclusively via a live audio webcast. The decision to hold a virtual-only Annual Meeting was prompted by the public health impact of the coronavirus pandemic and to support the health and safety of the Company’s stockholders, employees and communities.

Stockholders of record as of the close of business on October 13, 2020 can join the meeting via the Internet at www.virtualshareholdermeeting.com/CLCT2020 by using the 16-digit control number included on the proxy card, voting instruction form, or notice previously received. Any stockholder that holds its shares through a bank or broker or other nominee holder, and does not have a control number, should contact the bank, broker or other nominee holder to obtain that number. Stockholders are encouraged to log in to the website by 9:45 a.m. (Pacific Time) on the day of the Annual Meeting to access and review meeting materials. Stockholders will be able to submit their questions through the meeting website and vote their shares electronically during the Annual Meeting by following the instructions on the meeting website during the Annual Meeting. Access to the live webcast will also be made available on Collectors Universe’s Events and Presentations website page.

Other
Methods of
Vot
ing
at the Virtual Annual Meeting

Whether or not you plan to attend the virtual Annual Meeting, please do not wait until the date of the Annual Meeting to vote your shares. Instead, vote as soon as possible, by signing, dating and returning the proxy card or voting instruction card that you received in the postage-paid envelope provided, or use the telephone or Internet voting instructions that are on the Notice of Availability of Internet Proxy Materials mailed to you and on proxy card. If you hold your shares in an account at a bank, broker, dealer or other nominee, you will need to follow the instructions provided by your bank, broker, dealer or other nominee, to vote your shares. Voting your shares by any of the above methods will ensure that, if you are unable to “attend” the virtual Annual Meeting, your shares will be voted in accordance with your wishes. Voting now by one of these methods will not limit your right to change your vote later or to “attend” the virtual Annual Meeting.

If you have additional questions about the election of directors or the other proposals to be voted on at the Annual Meeting, about the Proxy Statement or about the virtual Annual Meeting, or if you would like additional copies of this Proxy Statement or if you need assistance voting your shares, please contact:

Collectors Universe, Inc.
P. O. Box 6280
Newport Beach, California 92658
Attention: Corporate Secretary
or
Call (949) 567-1157

About Collectors Universe

Collectors Universe, Inc. is a leading provider of value-added services to the collectibles markets. The Company authenticates and grades collectible coins, trading cards, event tickets, autographs and memorabilia). The Company also compiles and publishes authoritative information about United States and world coins, collectible trading cards and sports memorabilia and operates its CCE dealer-to-dealer Internet bid-ask market for certified coins and its Expos trade show and conventions business. This information is accessible to collectors and dealers at the Company’s website, http://www.collectorsuniverse.com, and is also published in print. 

Contacts

Shelton Group
Leanne K. Sievers
949-224-3874
[email protected]

MacKenzie Partners, Inc.
Bob Marese
212-929-5405
[email protected]

SAN FRANCISCO, Nov. 24, 2020 (GLOBE NEWSWIRE) — 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that Rohan Palekar, the company’s Chief Executive Officer, will participate in 1×1 meetings with investors at the Piper Sandler 32nd Annual Virtual Healthcare Conference on Wednesday, December 2, 2020. The conference will take place December 1-3, 2020. An archived webcast of the fireside chat is accessible in the investor section of 89bio’s website.

About 89bio

89bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases. The company’s lead product candidate, BIO89-100, is a specifically engineered glycoPEGylated analog of FGF21. BIO89-100 is being developed for the treatment of nonalcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG). 89bio is headquartered in San Francisco with operations in Herzliya, Israel.

Investor Contact:

Ryan Martins
Chief Financial Officer
[email protected]

Media Contact:

Peter Duckler
773-343-3069
[email protected]

— Groundbreaking; Sustainability; Environmental Upside —

Dallas, TX, Nov. 24, 2020 (GLOBE NEWSWIRE) — via NewMediaWire
 — NaturalShrimp, Inc. (OTCQB: SHMP), the aquaculture Company that has developed and patented the first commercially operational RAS (Recirculating Aquaculture System) for shrimp, announced today that it has finalized a joint venture between NaturalShrimp, Inc. and Ecoponex Systems International, LLC. This was announced in a Letter of Intent on October 12, 2020. This joint venture will utilize and combine the growing technology of NaturalShrimp with the Renewable Energy Efficient Farms (“REEF”) technology owned by Ecoponex. 

Ecoponex will maintain a 49% stake in the new company, with NaturalShrimp having a 51% interest. As part of the agreed upon terms of the joint venture, Ecoponex shall provide production facilities with its REEF technology for mutually approved locations based upon the cost and space estimates provided by NaturalShrimp. Additionally, Ecoponex shall contribute funding for the transaction and it shall be the sole responsibility of Ecoponex to arrange financing to fund the design, procurement, construction and startup of each NaturalShrimp growing facility approved by the managers. 

Ecoponex shall also bear responsibility for obtaining all necessary local, state and Federal permits necessary to construct and operate the Facility and to market and sell shrimp. NaturalShrimp will grant a royalty free license to the company to allow its proprietary shrimp growing technology and production benchmarks. NaturalShrimp will also provide any of its personnel as may be necessary to design, construct and commence operations and start-up as well as ongoing operations and marketing of shrimp produced at the facility. Lastly, NaturalShrimp will provide a performance guarantee that each facility will meet the production volumes that have been requested by Ecoponex, based upon the cost and space requirements provided to Ecoponex.

“We have worked diligently towards the close of this groundbreaking relationship between NaturalShrimp and Ecoponex,” said Gerald Easterling, CEO of NaturalShrimp. “We believe our technology platform, coupled with Ecoponex’s revolutionary approach to sustainability, provides us a perfect platform for this partnership.  We will update all stakeholders as we commence this venture,” added Mr. Easterling. 

“We are incredibly excited to have completed this joint venture with Ecoponex,” said William Delgado, CFO of NaturalShrimp. “We feel that their REEF technology combined with the aquaculture technology developed by our Company will provide environmental benefits for the climate and ultimately help us reduce our carbon footprint,” added Mr. Delgado.

“For Ecoponex, this joint venture represents a significant milestone in the evolution of our company that reflects the best-in-class approach we’ve taken to closely collaborate and align ourselves with innovators and leaders in the rapidly growing aquaculture industry like NaturalShrimp,” commented Benjamin Brant, CEO. “Toward this end, we believe NaturalShrimp’s patented growing technology not only offers us distinct competitive advantages in the marketplace for fresh organic seafood, but is a perfect fit for our unique closed-loop REEF process where we develop aquaculture projects designed as truly sustainable and self-reliant net-zero energy, water, waste and carbon operations. This is the ultimate goal of our collaboration that could make us one of the lowest cost, most efficient and profitable producers of preferred consumer products in the high-tech aquaculture and fresh food-tech industry,” Mr. Brant added.

About Ecoponex Systems International, LLC: Ecoponex is a privately held company that is in the business of developing, financing, owning and operating REEF™ facilities to serve urban markets in the United States and world. REEFs utilize an integrated platform of proprietary, licensed, patented and patent-pending technologies designed as an integrated closed-loop process. This process efficiently and profitably produces healthy fresh food and renewable energy while recovering CO2, nutrients and clean water to make it a self-reliant net zero operation. REEFs address local environmental and organic waste problems for the benefit of communities, create new jobs, and offer educational/training opportunities and local sustainable economic development by establishing a circular economy with upcycling and repurposing waste. 

About NaturalShrimp: NaturalShrimp, Inc. is a publicly traded aqua-tech Company, headquartered in Dallas, with production facilities located near San Antonio, Texas. The Company has developed the first commercially viable system for growing shrimp in enclosed, salt-water systems, using patented technology to produce fresh, never frozen, naturally grown shrimp, without the use of antibiotics or toxic chemicals. NaturalShrimp systems can be located anywhere in the world to produce gourmet-grade Pacific white shrimp.

Forward-Looking Statements

This press release contains “forward-looking statements.” The statements contained in this press release that are not purely historical are forward-looking statements. Forward-looking statements give the Company’s current expectations or forecasts of future events. Such statements are subject to risks and uncertainties that are often difficult to predict and beyond the Company’s control and could cause the Company’s results to differ materially from those described. In some cases, forward-looking statements can be identified by terminology such as “may,” “should,” “potential,” “continue,” “expects,” “anticipates,” “intends,” “plans,” “believes,” “estimates,” and similar expressions. These statements include statements regarding moving forward with executing the Company’s global growth strategy.

The statements are based upon current beliefs, expectations, and assumptions and are subject to a number of risks and uncertainties, many of which are difficult to predict. The Company is providing this information as of the date of this press release and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise, except as required by law. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends affecting the financial condition of our business.

Forward-looking statements should not be read as a guarantee of future performance or results and will not necessarily be accurate indications of the times at, or by, which such performance or results will be achieved. Important factors that could cause such differences include but are not limited to the Risk Factors and other information set forth in the Company’s Annual Report on Form 10-K filed on March 30, 2015, and in our other filings with the U.S. Securities and Exchange Commission.

Contact:

Paul Knopick

[email protected]

940.262.3584

DENVER, Nov. 24, 2020 (GLOBE NEWSWIRE) — HighPoint Resources Corporation (“we”, “us”, or the “Company”) (NYSE: HPR) today announced that on November 19, 2020, it received written notification from the New York Stock Exchange (the “NYSE”) that it has regained compliance with the NYSE continued listing standard relating to the average closing price of the Company’s shares.

As previously disclosed, on March 13, 2020, the Company received formal notice from the NYSE that it was not in compliance with the NYSE’s continued listing standards as a result of the average closing price of the Company’s common stock being less than $1.00 per share over a consecutive 30 trading-day period. The Company regained compliance after its average closing share price for the 30 trading-day period ending November 19, 2020 was above the NYSE’s minimum requirement of $1.00 per share.

As reported on November 10, 2020, the Company received a separate notice from the NYSE that it is no longer in compliance with the NYSE continued listing standards set forth in Section 802.01B of the NYSE’s Listed Company Manual due to the fact that the Company’s average global market capitalization over a consecutive 30 trading-day period was less than $50 million and, at the same time, its stockholders’ equity was less than $50 million. In accordance with NYSE procedures, the Company intends to submit a plan to the NYSE within 45 days of receipt of the notice advising the NYSE of definitive action it has taken, or is taking, to bring it into compliance within 18 months of receipt of the notice. The Company’s common stock will continue to be listed and traded on the NYSE during the applicable cure period under the common stock trading symbol “HPR.”

ABOUT
HIGHPOINT RESOURCES
CORPORATION

HighPoint Resources Corporation (NYSE: HPR) is a Denver, Colorado based company focused on the development of oil and natural gas assets located in the Denver-Julesburg Basin of Colorado. Additional information about the Company may be found on its website www.hpres.com.

Company contact: Larry C. Busnardo, Vice President, Investor Relations, 303-312-8514

Vancouver, B.C., Nov. 24, 2020 (GLOBE NEWSWIRE) — Lomiko Metals Inc. (“Lomiko”) (TSX-V: LMR, OTC: LMRMF, FSE: DH8C) is focused on the exploration and development of flake graphite in Quebec for the new green economy.  Lomiko is pleased to announce the Lomiko Technical, Safety and Sustainability Committee (“LTSSC”) has recommended the acceptance of a Proposal by SGS Canada Inc. to conduct a Metallurgical Process Development Program to the Board of Directors.  This Program has been accepted and approved by the Lomiko Board.

SGS Metallurgical Process Development Plan

Lomiko plans to ship four composites weighing 30 – 35 kg each consisting of high-grade and low-grade samples from the Refractory and the Graphene Battery mineralized zones will be shipped to SGS in Lakefield.  The main scope of the work program includes:

• Sample Preparation
• Chemical Characterisation
• Comminution Testing
• Flowsheet Development
• Environmental Testing 

The samples will be stage-crushed in a series of jaw and cone crushers to minimize the risk of flake degradation and fines generation.  Samples will be extracted for comminution testing, chemical characterization, and the generation of two Master composites. 

Bond ball mill grindability tests will be carried out to establish grinding energy requirements to assist in the design of the preliminary comminution circuit. 

Scoping level flowsheet development testing will be carried out on the two Master composites to establish a conceptual flowsheet.  The primary objectives of the flowsheet development program are to maximize the graphite recovery into a flotation concentrate while minimizing flake degradation. The final concentrates will be subjected to size fraction analyses to determine the flake size distribution and total carbon grade profile of the two mineralized zones. 

The high-grade and low-grade samples of the two mineralized zones will be subjected to variability flotation testing using the flowsheet and conditions that were developed for the two Master composites. Since a flowsheet must be able to treat all domains encountered in a deposit, these variability tests serve the purpose of assessing the robustness of the proposed flowsheet. 

Static geochemical tests will be carried out to assess the acid-generating potential of the La Loutre tailings with and without a sulphide rejection circuit.

Lomiko’s Near Term Goals

 Graphite demand is expected to increase exponentially for the mined natural graphite material, as more is used in the production of spherical graphite for graphite in the anode portion of Electric Vehicle Lithium-ion batteries.

Lomiko completed a $ 750,000 financing October 23, 2020 and plans to work on its near-term goals:

 

1) Complete 100% Acquisition of the Property, currently 80% owned by Lomiko Metals.

2) Complete metallurgy and graphite characterization to confirm li-ion anode grade material.

3) Complete a Technical Report to confirm that the extent of the mineralization equals or surpasses the nearby Imerys Mine, owned by international mining conglomerate.

 A “technical report” means a report prepared and filed in accordance with this Instrument and Form 43-101F1 Technical Report, and includes, in summary form, all material scientific and technical information in respect of the subject property as of the effective date of the technical report;

 4) Complete Preliminary Economic Assessment (PEA)

 A PEA means a study, other than a pre-feasibility or feasibility study, that includes an economic analysis of the potential viability of mineral resources.

 For more information on Lomiko Metals, Promethieus, review the website at www.lomiko.com, and www.promethieus.com, contact A. Paul Gill at 604-729-5312 or email: [email protected].

On Behalf of the Board

 “A. Paul Gill”

 Director, Chief Executive Officer

 We seek safe harbor.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange), accept responsibility for the adequacy or accuracy of this release.

 

Attachment

• graphite demand

A. Paul Gill
Lomiko Metals Inc. (TSX-V: LMR)
6047295312
[email protected]